Search
pemafibrate
Indications:
- hypertriglyceridemia
Clinical significance:
- does not lower incidence of cardiovascular events
Mechanism of action:
- selective peroxisome proliferator-activated receptor alpha modulator
- reduces triglyceride levels
- improves other lipid levels
- VLDL cholesterol, remnant cholesterol, apolipoprotein C3
Interactions
drug adverse effects of anti-hyperlipidemic agents
monitor with fibrates
General
fibrate
References
- Boswoth T
Triglyceride Lowering Fails to Show CV Benefit in Large Fibrate Trial.
Twenty-Five Percent Reduction Has No Effect.
Medscape. Nov 5, 2022
https://www.medscape.com/viewarticle/983610
- Das Pradhan A et al.
Triglyceride lowering with pemafibrate to reduce cardiovascular risk.
N Engl J Med 2022 Nov 5; [e-pub].
PMID: 36342113
https://www.nejm.org/doi/10.1056/NEJMoa2210645